amiodarone has been researched along with fluconazole in 28 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (3.57) | 18.2507 |
2000's | 10 (35.71) | 29.6817 |
2010's | 16 (57.14) | 24.3611 |
2020's | 1 (3.57) | 2.80 |
Authors | Studies |
---|---|
Topliss, JG; Yoshida, F | 1 |
Gao, F; Lombardo, F; Shalaeva, MY; Tupper, KA | 1 |
Gao, F; Lombardo, F; Obach, RS; Shalaeva, MY | 2 |
Furuya, K; Lan, LB; Sanglard, D; Schuetz, EG; Schuetz, JD; Yasuda, K | 1 |
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
Lombardo, F; Obach, RS; Waters, NJ | 1 |
Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
Ekins, S; Williams, AJ; Xu, JJ | 1 |
Annand, R; Gozalbes, R; Jacewicz, M; Pineda-Lucena, A; Tsaioun, K | 1 |
Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
Gibaldi, M | 1 |
Beaudry, V; Cunningham, K; Gupta, SS; Rao, R; Rulli, S; Ton, VK | 1 |
Avorn, J; Fischer, MA; Solomon, DH; Teich, JM | 1 |
Gamarra, S; Park, S; Perlin, DS; Rao, R; Rocha, EM; Zhang, YQ | 1 |
Gamarra, S; Garcia-Effron, G; Park, S; Perlin, DS; Rao, R; Zhang, YQ | 1 |
Bruggisser, M; Franz, CC; Krähenbühl, S; Rätz Bravo, AE | 1 |
Baxter, BK; Butts, A; Chabrier-Rosello, Y; DiDone, L; Koselny, K; Krysan, DJ; Wellington, M | 1 |
Angelo, MR; Brilhante, RS; Cavalcanti, BC; da Silva, CR; de Andrade Neto, JB; de Moraes, MO; Grangeiro, TB; Lobo, MD; Macedo, DS; Magalhães, HI; Nobre Júnior, HV; Sidrim, JJ | 1 |
Andersen, SE; Buch, T | 1 |
de Abajo, FJ; Gaist, D; Martín-Pérez, M; Rodríguez, LAG | 1 |
Barcellos, VA; Frank, LA; Garcia, AWA; Guterres, SS; Kinskovski, UP; Kmetzsch, L; Marques, BM; Motta, H; Oliveira, NK; Pohlmann, AR; Reuwsaat, JCV; Schrank, A; Squizani, ED; Staats, CC; Vainstein, MH | 1 |
2 review(s) available for amiodarone and fluconazole
Article | Year |
---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Drug interactions: part II.
Topics: Amiodarone; Biological Availability; Dapsone; Didanosine; Drug Interactions; Fluconazole; Food; Humans; Intestinal Absorption; Ketoconazole; Pharmaceutical Preparations; Rifampin | 1992 |
26 other study(ies) available for amiodarone and fluconazole
Article | Year |
---|---|
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
ElogD(oct): a tool for lipophilicity determination in drug discovery. 2. Basic and neutral compounds.
Topics: 1-Octanol; Chromatography, High Pressure Liquid; Pharmaceutical Preparations; Solubility; Water | 2001 |
Prediction of volume of distribution values in humans for neutral and basic drugs using physicochemical measurements and plasma protein binding data.
Topics: Blood Proteins; Chemical Phenomena; Chemistry, Physical; Half-Life; Humans; Hydrogen-Ion Concentration; Models, Biological; Pharmaceutical Preparations; Pharmacokinetics; Protein Binding | 2002 |
Interaction of cytochrome P450 3A inhibitors with P-glycoprotein.
Topics: Animals; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; Cell Line; Cells, Cultured; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Dihydroergocryptine; Drug Interactions; Enzyme Inhibitors; Fluconazole; Humans; Mice; Mice, Knockout; Microsomes, Liver; Oxidoreductases, N-Demethylating; Recombinant Proteins; Reserpine; Swine; Tissue Distribution; Transfection; Vinblastine | 2002 |
Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.
Topics: Algorithms; Blood Proteins; Half-Life; Humans; Hydrogen-Ion Concentration; Models, Biological; Pharmaceutical Preparations; Pharmacokinetics; Protein Binding; Statistics as Topic; Tissue Distribution | 2004 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
QSAR-based permeability model for drug-like compounds.
Topics: Caco-2 Cells; Cell Membrane Permeability; Drug Discovery; Humans; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2011 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Antifungal activity of amiodarone is mediated by disruption of calcium homeostasis.
Topics: Amiodarone; Antifungal Agents; Calcineurin; Calcium; Calcium Channels; Calcium-Binding Proteins; Calcium-Transporting ATPases; Drug Synergism; Fluconazole; Gene Deletion; Homeostasis; Miconazole; Molecular Chaperones; Mutation; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins; TRPC Cation Channels | 2003 |
Conversion from intravenous to oral medications: assessment of a computerized intervention for hospitalized patients.
Topics: Administration, Oral; Amiodarone; Drug Therapy, Computer-Assisted; Fluconazole; Humans; Infusions, Intravenous; Levofloxacin; Medication Systems, Hospital; Metronidazole; Ofloxacin; Practice Patterns, Physicians'; Ranitidine; Reminder Systems | 2003 |
Mechanism of the synergistic effect of amiodarone and fluconazole in Candida albicans.
Topics: Amiodarone; Animals; Antifungal Agents; Calcium; Candida albicans; Candidiasis; Down-Regulation; Drug Resistance, Fungal; Drug Synergism; Enzyme Inhibitors; Ergosterol; Female; Fluconazole; Gene Expression Profiling; Genes, Fungal; Hyphae; Lysosomes; Mice; Mice, Inbred BALB C; Up-Regulation; Vacuoles | 2010 |
Requirement for ergosterol in V-ATPase function underlies antifungal activity of azole drugs.
Topics: Amiodarone; Animals; Antifungal Agents; Candida albicans; Drug Synergism; Enzyme Inhibitors; Ergosterol; Female; Fluconazole; Mice; Mice, Inbred BALB C; Protons; Saccharomyces cerevisiae; Vacuolar Proton-Translocating ATPases; Vacuoles | 2010 |
[Rhabdomyolysis associated with atorvastatin combined with amiodarone and fluconazole].
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Anticholesteremic Agents; Antifungal Agents; Atorvastatin; Coronary Artery Bypass, Off-Pump; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Dose-Response Relationship, Drug; Drug Interactions; Drug Therapy, Combination; Fluconazole; Heptanoic Acids; Humans; Kidney Failure, Chronic; Male; Metabolic Clearance Rate; Middle Aged; Postoperative Complications; Pyrroles; Rhabdomyolysis | 2011 |
A repurposing approach identifies off-patent drugs with fungicidal cryptococcal activity, a common structural chemotype, and pharmacological properties relevant to the treatment of cryptococcosis.
Topics: Adenylate Kinase; Amiodarone; Animals; Antifungal Agents; Calmodulin; Cells, Cultured; Cryptococcosis; Cryptococcus neoformans; Drug Synergism; Fluconazole; Fungal Proteins; High-Throughput Screening Assays; Humans; Hydrophobic and Hydrophilic Interactions; Mice; Microbial Sensitivity Tests; Patents as Topic; Phagocytes; Small Molecule Libraries; Structure-Activity Relationship; Suloctidil; Thioridazine | 2013 |
Synergistic effects of amiodarone and fluconazole on Candida tropicalis resistant to fluconazole.
Topics: Amiodarone; Antifungal Agents; Candida tropicalis; Drug Resistance, Fungal; Drug Synergism; Fluconazole; Microbial Sensitivity Tests | 2013 |
[Combination therapy with fluconazole and other QTc-prolonging drugs increase the QTc interval].
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Anti-Bacterial Agents; Antifungal Agents; Clarithromycin; Combined Modality Therapy; Drug Interactions; Electrocardiography; Fluconazole; Heart Rate; Humans; Long QT Syndrome; Male | 2015 |
Population Impact of Drug Interactions with Warfarin: A Real-World Data Approach.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amiodarone; Anticoagulants; Carbamazepine; Databases, Factual; Drug Interactions; Female; Fluconazole; Follow-Up Studies; Humans; International Normalized Ratio; Male; Miconazole; Middle Aged; Nystatin; Primary Health Care; Retrospective Studies; United Kingdom; Warfarin; Young Adult | 2018 |
New nanotechnological formulation based on amiodarone-loaded lipid core nanocapsules displays anticryptococcal effect.
Topics: Amiodarone; Animals; Antifungal Agents; Cryptococcosis; Fluconazole; Lipids; Mice; Microbial Sensitivity Tests; Nanocapsules; Nanotechnology | 2021 |